HomeInsightsPE

Ind-swift Laboratories Ltd PE Ratio

Ind-swift Laboratories Ltd PE Ratio

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

2.9 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB

PE

5.9

Last updated on: Nov 23, 2024

Key Highlights

  • The P/E Ratio of Ind-Swift Laboratories Ltd is 5.9 as of 23 Nov 9.00 AM .
  • The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.6 on March 2019 to 1.4 on March 2024 . This represents a CAGR of -22.77% over 6 years.
  • The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 101.85 as of 22 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Ind-Swift Laboratories Ltd

No data available

Company Fundamentals for Ind-Swift Laboratories Ltd

No data available

Image

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB

Share Price

₹ 101.85

-2.05 (-1.97%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Ind-Swift Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Ind-Swift Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024101.85
21 Nov 2024103.9
19 Nov 2024106
18 Nov 2024104.05
14 Nov 2024106
13 Nov 2024106.7
12 Nov 2024108.5
11 Nov 2024110.55
08 Nov 2024112.5
07 Nov 2024114

SWOT Analysis Of Ind-Swift Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ind-Swift Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Ind-Swift Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Ind-Swift Laboratories Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Ind-Swift Laboratories Ltd

No data available

* All values are in crore

Historical Revenue of Ind-Swift Laboratories Ltd

No data available

* All values are in crore

Historical EBITDA of Ind-Swift Laboratories Ltd

No data available

* All values are in crore

Historical Net Profit of Ind-Swift Laboratories Ltd

No data available

* All values are in crore

Historical Dividend Payout of Ind-Swift Laboratories Ltd

No data available

* All values are in %

About Ind-Swift Laboratories Ltd

  • Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India.
  • The company manufactures and sells active pharmaceutical ingredients (API).
  • Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic).
  • The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA. Ind-Swift Laboratories Ltd was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
  • Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

Ind-Swift Laboratories Ltd News Hub

News

Ind-Swift Laboratories consolidated net profit declines 94.55% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 94.55% to Rs 0.94 crore in the quarter ended...

Read more

2024-08-13 00:00:00

News

Ind-Swift Laboratories standalone net profit declines 63.70% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 63.70% to Rs 6.19 crore in the quarter ended...

Read more

2024-08-13 00:00:00

News

Ind-Swift Laboratories to discuss results

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 ...

Read more

2024-08-03 00:00:00

News

Ind-Swift Laboratories to hold AGM

Ind-Swift Laboratories announced that the Annual General Meeting (AGM) of the company will...

Read more

2024-09-03 00:00:00

News

Ind-Swift Laboratories to declare Quarterly Result

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 11 ...

Read more

2024-11-08 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Ind-Swift Laboratories Ltd

What is the current PE Ratio of Ind-Swift Laboratories Ltd?

The Current PE Ratio of Ind-Swift Laboratories Ltd is 5.89 as on 23 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 23 Nov 2024.

What was the PE Ratio of Ind-Swift Laboratories Ltd last year?

The PE Ratio of Ind-Swift Laboratories Ltd was 6.94 last year, now the PE ratio is 5.89, showing a year-on-year growth of -15.1%.

What does the PE Ratio of Ind-Swift Laboratories Ltd indicate about its stock?

The PE Ratio of Ind-Swift Laboratories Ltd is 5.89. This ratio indicates that investors are willing to pay 5.89 times the earnings per share for each share of Ind-Swift Laboratories Ltd.

What is the PE Ratio Growth of Ind-Swift Laboratories Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Ind-Swift Laboratories Ltd grew by -15.1% whereas, the EPS ratio grew by -56.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*